https://stockhub.co/index.php?action=history&feed=atom&title=Cantabio_Pharmaceuticals%2C_Inc. 2026-05-28T16:59:10Z Revision history for this page on the wiki MediaWiki 1.43.5 https://stockhub.co/index.php?title=Cantabio_Pharmaceuticals,_Inc.&diff=59428&oldid=prev 2022-09-02T05:04:24Z

<p>Created page with &quot;== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; == Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson&#039;s disease (PD), Alzheimer&#039;s disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the trea...&quot;</p> <p><b>New page</b></p><div>== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; ==<br /> <br /> Cantabio Pharmaceuticals, Inc., a preclinical stage biotechnology company, focuses on the research, development, and commercialization of novel therapies for Parkinson&#039;s disease (PD), Alzheimer&#039;s disease (AD), and other related diseases. Its lead programs include CB101, a DJ-1 targeting small molecule pharmacological chaperone for use in the treatment of PD; CB201, a CNS penetrant engineered DJ-1 protein for use in the treatment of PD; CB301, a Tau protein targeting small molecule pharmacological chaperone for use in the treatment of AD; and CB401, an Aß targeting small molecule pharmacological chaperone for use in the treatment of AD. The company has a collaboration agreement with Luxembourg Institute of Health to research the therapeutic targeting of the DJ-1 - protein to treat immune associated diseases. The company was founded in 2009 and is based in Palo Alto, California.<br /> <br /> == References and notes == <br /> [[Category:Thesis]]<br /> __INDEX__</div>

95.149.241.133